SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$9.10 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2025-11-13
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$2.30M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$3.80M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$3.00M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-09-30 was $1.31M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$9.54M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was $1.69M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$6.10M derived: sum of 2 quarters · filed 2025-11-13 | -$9.10M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$6.80M 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | -$3.00M 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | -$9.54M 10-K · filed 2025-02-26 | |||
| 2023-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.36M derived: sum of 2 quarters · filed 2024-11-13 | $3.54M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-09-04 | $2.23M 10-Q · filed 2024-09-04 | ||
| 2023-03-31 | $1.18M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $1.69M 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |